A decision brief from Fact.MR for CBD manufacturers, cannabis companies, wellness brands, pharmaceutical businesses, ingredient suppliers, procurement leaders, retail category managers and investors.

Rockville, Maryland, 4 November 2026 – The global CBD market is valued at USD 13.5 billion in 2025 and is projected to reach USD 39.0 billion by 2035, expanding at a CAGR of 11.2% during the forecast period, according to Fact.MR. The market is expected to increase by USD 25.5 billion over the decade, representing total growth of 188.9%.

Market expansion reflects increasing regulatory acceptance, growing consumer awareness of CBD applications, expanding product innovation and rising adoption through mainstream retail channels. Demand for wellness-oriented products, alongside developments in extraction technologies, quality assurance and third-party testing, is influencing the competitive landscape.

Tinctures and oils account for 36% of product-type revenue in 2025, making them the leading product category. Dispensary and licensed retail channels represent 44% of distribution-channel revenue, highlighting the importance of regulated retail access, consumer education and compliance in CBD product distribution.

Manufacturers, procurement teams and investors can examine the latest market forecasts, segment opportunities and country-level growth prospects in Fact.MR's research.

Get a Sample of the Detailed Market Study:

The Short Version

• The global CBD market is projected to increase from USD 13.5 billion in 2025 to USD 39.0 billion by 2035, expanding at a CAGR of 11.2%.
• Tinctures and oils account for 36% of product-type revenue in 2025, maintaining their leading position.
• Dispensary and licensed retail channels represent 44% of distribution-channel revenue in 2025.
• The United States leads the selected country growth forecasts at 12.8% CAGR. Mexico follows at 11.9%, while Germany records 10.6% and France 10.1%.
• Increasing regulatory acceptance, consumer awareness, mainstream retail adoption, product innovation and quality standardization are supporting market expansion.

Three Numbers That Matter

USD 39.0 billion: Projected global CBD market value by 2035.

36%: Share of 2025 product-type revenue attributed to tinctures and oils.

44%: Share of 2025 distribution-channel revenue represented by dispensary and licensed retail.

These figures point towards a market where product versatility, regulatory compliance and consumer confidence influence commercial opportunities. Manufacturers that invest in reliable extraction processes, standardized formulations and transparent quality testing can strengthen their position across established and emerging CBD distribution channels.

Where Growth Is Strongest

Fact.MR identifies seven country markets in its forecast. The United States records the highest projected growth, followed by Mexico. Germany and France represent important European opportunities, while the United Kingdom and Asian markets offer additional potential through regulatory development and specialized product applications.

• USA: CAGR of 12.8% (2025–2035) – Growth opportunity: Mainstream retail adoption, licensed distribution, wellness products and expanding CBD applications.
• Germany: CAGR of 10.6% (2025–2035) – Growth opportunity: Pharmaceutical-grade CBD, medical cannabis infrastructure and quality-standardized products.
• UK: CAGR of 9.4% (2025–2035) – Growth opportunity: Compliant wellness products, premium CBD offerings and specialized retail channels.
• Japan: CAGR of 8.5% (2025–2035) – Growth opportunity: Pharmaceutical research, quality-focused CBD development and controlled product applications.

Why These Markets Matter

USA: The United States leads global CBD market growth with a projected CAGR of 12.8%. State-level legalization, mature regulatory frameworks and established cannabis industry infrastructure are supporting demand across licensed dispensaries, wellness retailers and mainstream distribution channels. Growing consumer acceptance is also encouraging companies to expand product portfolios and strengthen their market presence.

Germany: Germany is projected to grow at a CAGR of 10.6%, supported by medical cannabis leadership, pharmaceutical-grade manufacturing standards and comprehensive regulatory frameworks. Healthcare system integration and demand for quality-focused products are creating opportunities for pharmaceutical companies and medical cannabis operators developing compliant CBD solutions.

UK: The United Kingdom is forecast to expand at a CAGR of 9.4%. Regulatory clarity initiatives, established wellness markets and increasing interest in CBD applications are supporting opportunities for compliant product manufacturers. Premium wellness retailers and specialized health stores provide important distribution channels for companies targeting quality-conscious consumers.

Japan: Japan is projected to register a CAGR of 8.5% through 2035. Pharmaceutical research capabilities, quality standards and a controlled approach to CBD development are supporting opportunities for research-grade and pharmaceutical-oriented products. Companies with specialized research and quality assurance capabilities can explore opportunities in this market.

Who Is Moving: Competitive Landscape and Key Players

The competitive landscape includes established cannabis companies, specialist CBD manufacturers and wellness-focused brands. Their market positions differ according to hemp sourcing, extraction capabilities, product quality, regulatory compliance, brand recognition and retail distribution.

Charlotte's Web leads the market with a 5.6% share, supported by its hemp-derived CBD portfolio, quality assurance initiatives and consumer education activities.

Key Players Profiled by Fact.MR

• Charlotte's Web
• Canopy Growth
• Curaleaf
• CV Sciences
• Green Roads
• Medterra
• Aurora Cannabis
• Tilray Brands
• Endoca
• Elixinol

Charlotte's Web focuses on hemp-derived CBD products, cultivation, extraction capabilities and retail distribution. Canopy Growth maintains a broad cannabis and CBD portfolio with international reach and pharmaceutical development activities.

Curaleaf participates in the market through its cannabis operations and CBD offerings. CV Sciences specializes in hemp-derived CBD products and wellness applications, while Green Roads emphasizes pharmacist-formulated CBD products.

Medterra focuses on broad-spectrum CBD products and mainstream retail positioning. These companies compete through product development, extraction technology, quality assurance, regulatory compliance and brand differentiation.

The competitive opportunity extends beyond product availability. Manufacturers must establish reliable sourcing, consistent CBD potency, transparent testing procedures and compliance with applicable market regulations. Companies that address these requirements can strengthen consumer confidence and improve their ability to access regulated distribution channels.

Where to Act

Expand Tincture and Oil Portfolios: This segment accounts for 36% of product-type revenue in 2025. Manufacturers can focus on formulation consistency, precise dosing formats, product stability and extraction quality. Investments in standardized production processes can support differentiation across established CBD product categories.

Strengthen Licensed Retail Distribution: Dispensary and licensed retail channels represent 44% of distribution-channel revenue. Manufacturers can develop partnerships with regulated retailers and strengthen distribution capabilities through product documentation, staff education and compliance-focused supply arrangements.

Invest in Third-Party Testing and Quality Standardization: Product reliability remains an important factor in CBD market development. Companies can strengthen quality assurance through independent laboratory testing, potency verification, contamination screening and transparent certificates of analysis. These measures can support product credibility and regulatory compliance.

Develop Innovative CBD Product Categories: Opportunities are emerging across beverages, cosmetics, pet products and functional foods. Manufacturers can evaluate specialized formulation technologies and product development capabilities to address different consumer applications while complying with relevant product-specific regulations.

Prioritise Pharmaceutical-Grade Capabilities: Germany's projected 10.6% CAGR and Japan's 8.5% CAGR highlight opportunities in quality-focused and research-oriented applications. Companies can strengthen manufacturing standards, research partnerships and documentation systems to address requirements in specialized markets.

Strengthen Extraction and Formulation Technologies: Investments in extraction efficiency, formulation consistency and manufacturing controls can improve product quality. Companies can focus on reliable processing systems and standardized specifications to serve distributors and regulated retail businesses.

Where to Be Careful

• Regulatory Complexity: CBD regulations differ across countries and product categories. Companies must monitor applicable rules governing cultivation, extraction, product composition, marketing, distribution and permitted applications.
• Quality Standardization: Variations in CBD potency, extraction methods and product composition can affect consistency. Manufacturers need reliable testing procedures and documented quality controls.
• Consumer Education: Limited understanding of CBD products, their permitted applications and appropriate usage can affect consumer confidence and market adoption.
• Product Safety: Contamination risks and inconsistent product formulations can create commercial and compliance challenges. Third-party testing and transparent product documentation are important safeguards.
• Distribution Restrictions: Access to mainstream retail channels can depend on regulatory approvals, product classification and retailer requirements. Companies must evaluate market-specific distribution conditions before expansion.
• Competitive Pressure: Established cannabis businesses and specialist wellness brands compete through pricing, product innovation, quality and brand recognition. New entrants need differentiated offerings and reliable distribution capabilities.

The commercial priority should be to balance product innovation with quality assurance, regulatory compliance and consumer education. Manufacturers must establish reliable production standards and market-specific distribution strategies before expanding into new geographical territories.

Analyst Perspective

S.N. Jha, Principal Consultant at Fact.MR, is the report's lead analyst.

The report identifies increasing regulatory acceptance, consumer awareness, mainstream retail adoption and expanding product applications as important factors shaping the CBD market. Its analysis also highlights the growing importance of tinctures and oils, licensed retail distribution, extraction technologies and third-party testing.

The findings underline the importance of understanding regulatory requirements and product quality expectations before entering new markets. Manufacturers must consider formulation consistency, independent testing, transparent documentation and distribution restrictions when developing international expansion strategies.

Unlock Actionable Insights from the Complete Report:

Questions for Your Next Planning Meeting

• Which CBD product categories offer the strongest opportunities for expanding our product portfolio?
• Can our existing manufacturing and quality assurance systems support consistent CBD potency and third-party testing requirements?
• How can we strengthen distribution partnerships with licensed retailers and regulated market participants?
• Which extraction and formulation technologies can improve product consistency and manufacturing efficiency?
• Which international markets offer the strongest opportunities for expanding our CBD business while maintaining regulatory compliance?

Explore More Related Studies Published by Fact.MR Research

Processed Cheese Market

Cocoa Market

Gluten-free Bread Market

Snacks Market

About Fact.MR

Fact.MR is a market research and consulting firm providing market intelligence, industry analysis and strategic insights to businesses across multiple sectors.

Its research covers market sizing, forecasts, competitive landscapes, segment analysis, country-level opportunities and industry developments. Fact.MR supports manufacturers, investors, procurement teams and business leaders with information for strategic planning and commercial decision-making.

Media Contact

Fact.MR
Email: sales@factmr.com
Website: https://www.factmr.com